Eisai Launches Acicept Jelly Formulation
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Eisai Dec. 2 launched a jelly formulation of its blockbuster drug Aricept (donepezil) for Alzheimer's disease. The new formulation comes in three dosages: 3mg, 5mg and 10mg. Eisai hopes to maximize Aricpet product value through adding new formulations before the basic patent for the drug expires in November 2010. The company also launched a fine granule formulation. Eisai said the addition will make Aricept easier to take for senior AD patients who have difficulty swallowing. (Click here for more - Japanese language